Trials / Conditions / Familial Chylomicronemia Syndrome

Familial Chylomicronemia Syndrome

11 registered clinical trials studyying Familial Chylomicronemia Syndrome.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects NCT06471543	Ikaria Bioscience Pty Ltd	Phase 1 / Phase 2
Completed	A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia NCT05902598	Visirna Therapeutics HK Limited	Phase 3
Active Not Recruiting	A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemi NCT05185843	Ionis Pharmaceuticals, Inc.	Phase 3
Active Not Recruiting	A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndr NCT05130450	Ionis Pharmaceuticals, Inc.	Phase 3
Completed	A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicrone NCT04568434	Ionis Pharmaceuticals, Inc.	Phase 3
Completed	InFocus France Epidemiological Study of Health Burden in Major Hypertriglyceridemia NCT04223908	New French Society of Atherosclerosis	—
Completed	Medical Complications in Familial and Multifactorial Chylomicronaemia Syndromes NCT03912181	Hospices Civils de Lyon	—
Completed	Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS) NCT03360747	Akcea Therapeutics	Phase 2
Completed	The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familia NCT02658175	Akcea Therapeutics	Phase 3
Completed	The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronem NCT02211209	Ionis Pharmaceuticals, Inc.	Phase 3
Approved For Marketing	Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS) NCT06360237	Ionis Pharmaceuticals, Inc.	—